PNeoVCA
Phase 1/2 Recruiting
132 enrolled
Tebentafusp-tebn With LDT in Metastatic UM
Phase 1/2 Recruiting
109 enrolled
Sargramostim (GM-CSF) + PD-1
Phase 2 Withdrawn
Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic Anemia
Phase NA Completed
10 enrolled
Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma
Phase 3 Withdrawn
Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
Phase 1 Completed
GIPI
Phase 2 Completed
29 enrolled
Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma
Phase 4 Completed
8 enrolled 5 charts
Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant Melanoma
Phase 1 Completed
18 enrolled
Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma
Phase 2 Withdrawn
Radiofrequency Therapy-Induced Endogenous Heat-Shock Proteins With or Without Radiofrequency Ablation or Cryotherapy in Treating Patients With Stage IV Melanoma
Phase 1 Completed
11 enrolled
REO13 Melanoma With of Without GM-CSF
Phase 1/2 Withdrawn
Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma
Phase 2 Completed
52 enrolled 8 charts
Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer
Phase 1 Completed
7 enrolled
Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Phase 1 Completed
22 enrolled
Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
Phase 2 Completed
71 enrolled 12 charts
DCVaccineMel
Phase 2 Completed
56 enrolled
Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Phase 2 Completed
28 enrolled
Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Phase 1 Completed
40 enrolled
Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
Phase 2 Completed
Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma
Phase 2 Completed
40 enrolled 10 charts
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
Phase 2 Completed
7 enrolled
Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma
Phase 1/2 Completed
39 enrolled
Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery
Phase 2 Completed
48 enrolled
Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma
Phase 2 Terminated
25 enrolled
Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma
Phase 2 Completed
60 enrolled
Paclitaxel and GM-CSF in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
Phase 2 Suspended
42 enrolled
Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma
Phase 2 Completed
Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma
Phase 1/2 Completed
50 enrolled
Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma
Phase 2 Completed
20 enrolled 9 charts
Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma
Phase 2 Withdrawn
Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors
Phase 2 Completed
20 enrolled